Education
About Us
Working with TipRanks
Follow Us
Inhibrx Biosciences, Inc. (INBX)
:INBX
INBX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.81 - $30.23
Previous CloseN/A
Volume23.61K
Average Volume (3M)104.32K
Market Cap
$393.79M
Enterprise Value$140.95M
Total Cash (Recent Filing)$186.57M
Total Debt (Recent Filing)$7.51M
Price to Earnings (P/E)0.2
Beta0.49
Next Earnings
Nov 13, 2025EPS Estimate
-1.72Last Dividend Ex-Date
May 30, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)-1.85
Shares Outstanding14,485,421
10 Day Avg. Volume98,208
30 Day Avg. Volume104,317
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.36
Enterprise Value/Revenue100.68
Enterprise Value/Gross Profit-101.62
Enterprise Value/Ebitda-0.89
Forecast
1Y Price Target
$24.50Price Target Upside-7.79% Downside
Rating ConsensusHold
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Efficacy Of TreatmentOzekibart FOLFIRI combo shows 40% ORR, demonstrating effectiveness in heavily pretreated CRC patients.
Financial StabilityInhibrx is well capitalized with $196.3 million in cash, allowing continued development of its key treatments.
Bears Say
Adverse Effects31% of patients experienced an increase in alanine aminotransferase, indicating potential safety issues.
Safety ConcernsA patient passed away due to neutropenic sepsis, raising concerns about the safety profile of the treatment.
Inhibrx Biosciences Inc News
INBX FAQ
What was Inhibrx Biosciences, Inc.’s price range in the past 12 months?
Inhibrx Biosciences, Inc. lowest stock price was $10.80 and its highest was $30.23 in the past 12 months.
What is Inhibrx Biosciences, Inc.’s market cap?
Inhibrx Biosciences, Inc.’s market cap is $393.79M.
When is Inhibrx Biosciences, Inc.’s upcoming earnings report date?
Inhibrx Biosciences, Inc.’s upcoming earnings report date is Nov 13, 2025 which is in 56 days.
How were Inhibrx Biosciences, Inc.’s earnings last quarter?
Inhibrx Biosciences, Inc. released its earnings results on Aug 13, 2025. The company reported -$1.85 earnings per share for the quarter, beating the consensus estimate of -$2.76 by $0.91.
Is Inhibrx Biosciences, Inc. overvalued?
According to Wall Street analysts Inhibrx Biosciences, Inc.’s price is currently Overvalued.
Does Inhibrx Biosciences, Inc. pay dividends?
Inhibrx Biosciences, Inc. pays a Notavailable dividend of $0.85 which represents an annual dividend yield of N/A. See more information on Inhibrx Biosciences, Inc. dividends here
What is Inhibrx Biosciences, Inc.’s EPS estimate?
Inhibrx Biosciences, Inc.’s EPS estimate is -1.72.
How many shares outstanding does Inhibrx Biosciences, Inc. have?
Inhibrx Biosciences, Inc. has 14,485,421 shares outstanding.
What happened to Inhibrx Biosciences, Inc.’s price movement after its last earnings report?
Inhibrx Biosciences, Inc. reported an EPS of -$1.85 in its last earnings report, beating expectations of -$2.76. Following the earnings report the stock price went up 7.527%.
Which hedge fund is a major shareholder of Inhibrx Biosciences, Inc.?
Currently, no hedge funds are holding shares in INBX
Inhibrx Biosciences Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$24.50 (-7.79% Downside)
$24.50 (-7.79% Downside)
Hedge Fund Trend
Increased
By 218.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.43%
12-Months-Change
Fundamentals
Return on Equity
-113.71%
Trailing 12-Months
Asset Growth
-17.92%
Trailing 12-Months
Company Description
Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
Technical Analysis
Prothena
―
CytomX Therapeutics
―
Humacyte
―
Monte Rosa Therapeutics
―
Candel Therapeutics
―
Ownership Overview
15.46% Insiders
6.60% Mutual Funds
45.87% Other Institutional Investors
24.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---